专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1996020194A1 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF 审中-公开
标题翻译：新型喹啉衍生物及其药物组合物
公开(公告)号：WO1996020194A1
公开(公告)日：1996-07-04
申请号：PCT/JP1995002713
申请日：1995-12-27
申请人： YAMANOUCHI PHARMACEUTICAL CO., LTD. , TAKEUCHI, Makoto , NAITO, Ryo , HAYAKAWA, Masahiko , OKAMOTO, Yoshinori , YONETOKU, Yasuhiro , IKEDA, Ken , ISOMURA, Yasuo
发明人： YAMANOUCHI PHARMACEUTICAL CO., LTD.
IPC分类号： C07D453/02
CPC分类号： C07D221/12 , C07D453/02 , C09K19/3444
摘要： A quinuclidine derivative represented by general formula (I), a salt, N-oxide or quaternary ammonium salt thereof, and a medicinal composition containing the same, wherein the ring A represents optionally substituted aryl, cycloalkyl, cycloalkenyl, heteroaryl containing 1 to 4 heteroatoms selected from among oxygen, nitrogen and sulfur, or 5- to 7-membered saturated heterocycle; X represents a single bond or methylene; R represents halogeno, hydroxy, lower alkoxy, carboxy, lower alkoxycarbonyl, lower acyl, mercapto, lower alkylthio, sulfonyl, lower alkylsulfonyl, sulfinyl, lower alkylsulfinyl, sulfonamido, lower alkanesulfonamido, carbamoyl, thio-carbamoyl, mono- or di(lower alkyl)carbamoyl, nitro, cyano, amino, mono- or di(lower alkyl)amino, methylenedioxy, ethylenedioxy or lower alkyl optionally substituted by halogeno, hydroxy, lower alkoxy, amino or mono- or di(lower alkyl)amino; 1 is 0 or 1; m is an integer of 1 to 3; and n is an integer of 1 or 2. The compound has an antagonistic effect on muscarine M3 receptors and is useful as a preventive or remedy for urologic diseases, respiratory diseases or digestive diseases.
摘要翻译：由通式（I）表示的奎宁环衍生物，其盐，N-氧化物或季铵盐及含有该奎宁环衍生物的药物组合物，其中环A表示任选取代的芳基，环烷基，环烯基，含有1至4个杂原子的杂芳基选自氧，氮和硫，或5-至7-元饱和杂环; X表示单键或亚甲基; R代表卤代，羟基，低级烷氧基，羧基，低级烷氧基羰基，低级酰基，巯基，低级烷硫基，磺酰基，低级烷基磺酰基，亚磺酰基，低级烷基亚磺酰基，亚磺酰氨基，低级烷烃磺酰胺基，氨基甲酰基，硫代氨基甲酰基，氨基，硝基，氰基，氨基，一或二（低级烷基）氨基，亚甲二氧基，亚乙二氧基或任选被卤代，羟基，低级烷氧基，氨基或一或二（低级烷基）氨基取代的低级烷基; 1为0或1; m为1〜3的整数。并且n是1或2的整数。该化合物对毒蕈碱M3受体具有拮抗作用，并且可用作泌尿系统疾病，呼吸系统疾病或消化系统疾病的预防或治疗。

2. 发明申请

WO1998008820A1 BENZENESULFONE COMPOUNDS AND SALTS THEREOF 审中-公开
标题翻译：苯并呋喃酮化合物及其盐
公开(公告)号：WO1998008820A1
公开(公告)日：1998-03-05
申请号：PCT/JP1997002934
申请日：1997-08-25
申请人： YAMANOUCHI PHARMACEUTICAL CO., LTD. , YOKOTA, Masaki , KAWAZOE, Souichirou , OKAMOTO, Yoshinori , KUBOTA, Hirokazu , NAITO, Ryo , ARAKIDA, Yasuhito
发明人： YAMANOUCHI PHARMACEUTICAL CO., LTD.
IPC分类号： C07D215/12
CPC分类号： C07D215/14
摘要： Benzenesulfone compounds represented by general formula (I) or pharmaceutically acceptable salts thereof, useful as pharmaceuticals having a combination of leucotriene antagonism with thromboxane A2 antagonism and good oral absorbability, especially as agents for preventing and treating diseases and which leucotriene and thromboxane A2 participate, such as bronchial asthma, wherein B represents an optionally substituted quinolyl group; D represents an optionally substituted phenyl group; E represents a group represented by formulas (a), (b), or (c); one of A and A represents an optionally substituted methylene group or an optionally substituted ethylene group with the other representing a single bond, an optionally substituted methylene group, or an optionally substituted ethylene group, provided that when 1 is 1 and Y represents an optionally substituted phenylene group, each of A and A may represent a single bond; X represents an oxygen atom or a sulfur atom; Y represents an optionally substituted phenylene group, an optionally substituted phenyleneoxy group, or an optionally substituted spirocyclopropinyl group; Z represents a group represented by the formula: -CH=CH-, -CH2-CH2-, -CH2O-, or -O-CH2-; R represents a carboxyl group or tetrazolyl group which may be optionally substituted with an ester residue; 1, n, p, and q, which may be the same or different, are each 0 or 1; and m represents 1, 2, or 3.
摘要翻译：通式（I）表示的苯磺酸盐或其药学上可接受的盐，其可用作具有白三烯拮抗作用与血栓素A2拮抗作用的组合和良好的口服吸收性的药物，特别是作为预防和治疗疾病的药物以及白内障和血栓素A2参与的药物作为支气管哮喘，其中B表示任选取代的喹啉基; D表示任选取代的苯基; E表示由式（a），（b）或（c）表示的基团。 A 1和A 2之一表示任选取代的亚甲基或任选取代的亚乙基，另一个代表单键，任选取代的亚甲基或任选取代的亚乙基，条件是当1为1时 Y表示任意取代的亚苯基，A 1和A 2中的每一个可以表示单键; X表示氧原子或硫原子; Y表示任选取代的亚苯基，任选取代的亚苯基氧基或任选取代的螺环丙基; Z表示由下式表示的基团：-CH = CH-，-CH 2 -CH 2 - ， - CH 2 O - 或-O-CH 2 - ; R表示可任选被酯残基取代的羧基或四唑基; 1，n，p和q可以相同或不同，各自为0或1; m表示1,2或3。

3. 发明申请

WO1995028389A1 SPIRO COMPOUND AND MEDICINAL COMPOSITION THEREOF 审中-公开
标题翻译： SPIRO化合物及其药物组合物
公开(公告)号：WO1995028389A1
公开(公告)日：1995-10-26
申请号：PCT/JP1995000713
申请日：1995-04-12
申请人： YAMANOUCHI PHARMACEUTICAL CO., LTD. , KUBOTA, Hirokazu , OKAMOTO, Yoshinori , FUJII, Masahiro , KAKEFUDA, Akio , YAMAMOTO, Osamu , NAGAOKA, Hitoshi , IKEDA, Ken , ISOMURA, Yasuo
发明人： YAMANOUCHI PHARMACEUTICAL CO., LTD.
IPC分类号： C07D221/20
CPC分类号： C07D221/20 , C07D471/10 , C07D491/10 , C07D495/10
摘要： A spiro compound represented by general formula (I), a salt thereof, a hydrate thereof, or a solvate thereof, a typical example of which is the compound (a). It has an antagonistic effect against tachykinin receptors, especially substance P and/or neurokinin A receptors, and is useful as a preventive or remedy for respiratory diseases, central nervous system diseases, pains, and inflammatory diseases.
摘要翻译：由通式（I）表示的螺环化合物，其盐，其水合物或其溶剂化物，其典型实例是化合物（a）。它对速激肽受体，特别是物质P和/或神经激肽A受体具有拮抗作用，并且可用作呼吸系统疾病，中枢神经系统疾病，疼痛和炎性疾病的预防或治疗。

4. 发明申请

WO1994000438A1 NOVEL BENZODIAZEPINE DERIVATIVE 审中-公开
标题翻译：新的苯二甲酸衍生物
公开(公告)号：WO1994000438A1
公开(公告)日：1994-01-06
申请号：PCT/JP1993000844
申请日：1993-06-22
申请人： YAMANOUCHI PHARMACEUTICAL CO., LTD. , FERRING B.V. , SATOH, Masato , OKAMOTO, Yoshinori , KOSHIO, Hiroyuki , NISHIDA, Akito , MIYATA, Keiji , OHTA, Mitsuaki , RYDER, Hamish , KENDRICK, David, A. , SEMPLE, Graeme , SZELKE, Michael
发明人： YAMANOUCHI PHARMACEUTICAL CO., LTD. , FERRING B.V.
IPC分类号： C07D243/24
CPC分类号： C07D401/04 , C07D243/24 , C07D401/12 , C07D403/12
摘要： A novel benzodiazepine derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof. These compounds are useful as medicines, in particular, for treating and preventing diseases in which CCK-B receptor and gastrin receptor participate, because they have CCK-B receptor antagonism, gastrin receptor antagonism and the effect of inhibiting gastric juice secretion.
摘要翻译：一种由通式（I）表示的新型苯二氮卓衍生物或其药学上可接受的盐。这些化合物可用作药物，特别是用于治疗和预防CCK-B受体和胃泌素受体参与的疾病，因为它们具有CCK-B受体拮抗作用，胃泌素受体拮抗作用和抑制胃液分泌的作用。

5. 发明申请

WO1996006843A1 NOVEL NAPHTHYRIDINE DERIVATIVE AND MEDICINAL COMPOSITION THEREOF 审中-公开
标题翻译：新型萘啶衍生物和药物组合物
公开(公告)号：WO1996006843A1
公开(公告)日：1996-03-07
申请号：PCT/JP1995001700
申请日：1995-08-28
申请人： YAMANOUCHI PHARMACEUTICAL CO., LTD. , TAKAYAMA, Kazuhisa , IWATA, Masahiro , OKAMOTO, Yoshinori , AOKI, Motonori , NIWA, Akira , ISOMURA, Yasuo
发明人： YAMANOUCHI PHARMACEUTICAL CO., LTD.
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： A 1,8-naphthyridine derivative represented by general formula (I), and salt, hydrate and solvate thereof: the compound inhibits type IV phosphodiesterases and is useful as a preventive or remedy for respiratory diseases, inflammatory diseases, systemic or local joint diseases, proliferative diseases, inflammations accompanying organ transplantation, diseases associated with urination, and diseases wherein tumor necrosis factors (TNF) and other cytokines, such as IL-1 or IL-2, participate.
摘要翻译：由通式（I）表示的1,8-萘啶衍生物及其盐，水合物和溶剂化物：该化合物抑制IV型磷酸二酯酶，并且可用作呼吸系统疾病，炎性疾病，全身或局部关节疾病的预防或治疗，增殖性疾病，伴随器官移植的炎症，与排尿有关的疾病，以及肿瘤坏死因子（TNF）和其它细胞因子如IL-1或IL-2参与的疾病。

6. 发明申请

WO1992011246A1 NOVEL BENZODIAZEPINE DERIVATIVE 审中-公开
标题翻译：新的苯二甲酸衍生物
公开(公告)号：WO1992011246A1
公开(公告)日：1992-07-09
申请号：PCT/JP1991001720
申请日：1991-12-17
申请人： YAMANOUCHI PHARMACEUTICAL CO., LTD. , SATOH, Masato , KONDOH, Yutaka , OKAMOTO, Yoshinori , NISHIDA, Akito , HONDA, Kazuo , SAITO, Masayuki
发明人： YAMANOUCHI PHARMACEUTICAL CO., LTD.
IPC分类号： C07D243/24
CPC分类号： C07D401/06 , B65D83/0847 , B65H35/10 , B65H2701/11231 , C07D243/24 , C07D403/04 , C07D409/06
摘要： A novel benzodiazepine derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a process for producing the same. In formula (I), R represents optionally substituted aryl, five-membered monocyclic group, six-membered monocyclic group or aromatic heterocyclic group comprising five-membered and six-membered rings; and R represents optionally substituted aryl. The compound (I) has a CCK-B receptor antagonism and an action of inhibiting pentagastrin-stimulated gastric secretion and hence is useful in treating and preventing the diseases wherein a CCK-B receptor and a gastrin receptor participate.
摘要翻译：由通式（I）表示的新型苯并二氮杂衍生物，其药学上可接受的盐，其药物组合物及其制备方法。在式（I）中，R 1表示任选取代的芳基，五元单环基，六元单环基或包含五元和六元环的芳族杂环基; 且R 2表示任选取代的芳基。化合物（I）具有CCK-B受体拮抗作用和抑制五肽胃泌素刺激的胃分泌的作用，因此可用于治疗和预防CCK-B受体和胃泌素受体参与的疾病。

7. 发明专利

JP2002342145A AUTHENTICATION SYSTEM FOR ELECTROMAGNETIC RECORD, AND PROGRAM 失效
公开(公告)号：JP2002342145A
公开(公告)日：2002-11-29
申请号：JP2001147707
申请日：2001-05-17
申请人： OKAMOTO YOSHINORI
发明人： OKAMOTO YOSHINORI
IPC分类号： G06F12/14 , G06F12/00 , G06F21/24 , H04L9/32
摘要： PROBLEM TO BE SOLVED: To provide a safe electromagnetic record authentication system by which a burden of authenticating an accessing person can be reduced in a server and an electromagnetic record is not always requested to be stored in a client side. SOLUTION: This authentication system consists of an authentication client system and authentication storage server systems connected through the Internet, the authentication client system distributedly transmits fragment information prepared from an electromagnetic record to a plurality of authentication storage server systems, and also outputs restoration information needed to restore the electromagnetic record, the authentication storage server systems store the transmitted fragment information and transmit the fragment information and information showing authentication results to the authentication client system, and the authentication client system extracts the fragment information from the authentication storage server systems by using the restoration information and restores the electromagnetic record.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式